- Home
- PLSE
as 10-08-2025 3:42pm EST
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | HAYWARD |
| Market Cap: | 1.1B | IPO Year: | 2016 |
| Target Price: | $22.00 | AVG Volume (30 days): | 254.2K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.77 - $25.00 | Next Earning Date: | 10-29-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 700.00% |
Stock Insider Trading Activity of Pulse Biosciences Inc (DE) (PLSE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | PLSE | Chief Commercial Officer | Oct 2 '25 | Sell | $18.53 | 4,600 | $85,238.00 | 43,298 | |
| Danahy Kevin Patrick | PLSE | Chief Commercial Officer | Sep 19 '25 | Sell | $18.48 | 400 | $7,392.00 | 43,298 | |
| Danahy Kevin Patrick | PLSE | Chief Commercial Officer | Sep 18 '25 | Sell | $18.49 | 20,000 | $369,800.00 | 43,298 | |
| UECKER DARRIN | PLSE | Chief Technology Officer | Sep 17 '25 | Sell | $16.21 | 20,000 | $324,200.00 | 122,872 | |
| UECKER DARRIN | PLSE | Chief Technology Officer | Sep 16 '25 | Sell | $16.28 | 25,000 | $407,000.00 | 122,872 | |
| UECKER DARRIN | PLSE | Chief Technology Officer | Sep 15 '25 | Sell | $15.77 | 25,000 | $394,250.00 | 122,872 | |
| UECKER DARRIN | PLSE | Chief Technology Officer | Sep 12 '25 | Sell | $14.32 | 25,000 | $358,000.00 | 122,872 | |
| UECKER DARRIN | PLSE | Chief Technology Officer | Sep 11 '25 | Sell | $14.78 | 25,000 | $369,500.00 | 122,872 |
Latest Pulse Biosciences Inc (DE) News
PLSE Breaking Stock News: Dive into PLSE Ticker-Specific Updates for Smart Investing
Insider Monkey
8 days ago
Pulse Biosciences, Inc. (PLSE) Advances Cardiac Care with FDA-Approved Atrial Fibrillation Trial
Zacks
a month ago
Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study
Business Wire
a month ago
Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting
Simply Wall St.
4 months ago
Insider Purchases Worth US$2.70m See Losses As Pulse Biosciences Market Value Drops To US$1.1b
Business Wire
5 months ago
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
5 months ago
Pulse Biosciences, Inc. (NASDAQ:PLSE) insiders have significant skin in the game with 73% ownership
GuruFocus.com
5 months ago
Pulse Biosciences Inc (PLSE) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...
Business Wire
5 months ago
Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results
Compare PLSE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PLSE Pulse Biosciences Inc (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.